Business Context and Reporting Period
This Form 8-K Current Report was filed by Caribou Biosciences, Inc. on December 16, 2022, covering events occurring on December 15, 2022. The filing addresses a change in the Company's principal accounting officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Appointment of Principal Accounting Officer: Jason V. O'Byrne, the Company's Chief Financial Officer, was appointed as the principal accounting officer effective December 15, 2022.
- Role Transition: Ryan Fischesser, previously the Vice President of Finance and Controller and principal accounting officer, will continue in his role as Vice President of Finance and Controller but will no longer serve as the principal accounting officer.
- Section 16 Status: The Board of Directors determined that Ryan Fischesser is no longer considered an "officer" for purposes of Section 16 of the Securities Exchange Act of 1934 due to this change.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. It confirms there are no undisclosed arrangements or understandings regarding Mr. O'Byrne's selection and no material transactions involving him other than standard compensation arrangements described in the 2022 Proxy Statement.
Investor Verification Checklist
- Verify the biographical details of Jason V. O'Byrne in the Company's 2022 definitive proxy statement (Schedule 14A).
- Review the "Executive and Director Compensation" section of the 2022 Proxy for details on Mr. O'Byrne's compensation arrangements.
- Confirm the updated Section 16 reporting status for Ryan Fischesser.